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Purpose: The technology and sophistication of healthcare utilization databases have expanded 
over the last decade to include results of lab tests, vital signs, and other clinical information. 
This review provides an assessment of the methodological and analytical challenges of conduct-
ing chronic obstructive pulmonary disease (COPD) outcomes research in a national electronic 
medical records (EMR) dataset and its potential application towards the assessment of national 
health policy issues, as well as a description of the challenges or limitations.
Methods: An EMR database and its application to measuring outcomes for COPD are described. 
The ability to measure adherence to the COPD evidence-based practice guidelines, generated 
by the NIH and HEDIS quality indicators, in this database was examined. Case studies, before 
and after their publication, were used to assess the adherence to guidelines and gauge the con-
formity to quality indicators.
Results: EMR was the only source of information for pulmonary function tests, but low fre-
quency in ordering by primary care was an issue. The EMR data can be used to explore impact 
of variation in healthcare provision on clinical outcomes. The EMR database permits access to 
speciﬁ  c lab data and biometric information.
Conclusions: The richness and depth of information on “real world” use of health services for 
large population-based analytical studies at relatively low cost render such databases an attrac-
tive resource for outcomes research. Various sources of information exist to perform outcomes 
research. It is important to understand the desired endpoints of such research and choose the 
appropriate database source.
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Background
Healthcare utilization has expanded with the addition of electronically recording more 
clinical aspects of patients’ charts including results of lab tests, vital signs, and other 
clinical information. The type of information contained within databases and the num-
ber of retrospective data sources has increased in just a few short years leading to the 
increased desire to utilize retrospective database analysis for several purposes including 
disease outcomes and end-points of therapy. Comparisons of outcomes have been made 
with observational studies against randomized, controlled trials in various disease states 
and have shown similar results (Benson and Hartz 2000; Concato et al 2000). Benson 
and Hartz (2000) hypothesized that the improvement in results of observational studies 
may be due to more sophisticated selection of datasets and statistical methods. Assess-
ing disease states across different databases maximizes the strengths and minimizes 
the weaknesses of each individual database, which may be comparable to the effect 
of the multicenter aspect of a clinical trial. The objective of this study was to provide 
an assessment of the advantages and challenges of conducting chronic obstructive 
pulmonary disease (COPD) related outcomes research in a national EMR dataset and 
its potential application towards the assessment of national health policy issues.International Journal of COPD 2008:3(2) 324
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Methods
A national EMR database and its application to measuring 
outcomes for COPD are described. The ability of measuring 
adherence to the COPD evidence-based practice guidelines 
generated by the NIH and HEDIS quality indicators were 
examined using 2 case studies (GOLD 2005). A summary 
of the results and conclusions of these case studies are pro-
vided in Table 1.
Data source
The primary data source used for the case studies was the 
General Electric (GE) Centricity research database. Centricity 
EMR (Logician, Version 4.6, Hillsboro, Oregon, Medica-
Logic/Medscape, Inc, 1994) is an EMR used by over 20,000 
clinicians to manage 30 million patient records in 49 states. 
A subset of over 5,000 Centricity providers contributes data 
to the medical quality improvement consortium (MQIC) to 
create a research database. The MQIC represents a variety of 
practice types including solo practitioners, community clinics, 
academic medical centers, and large integrated delivery net-
works. Approximately two thirds of the participating clinicians 
practice primary care and others practice various specialties.
GE EMR data from 1996 to June of 2005 was available, 
and a subset of 1.1 million adult patients with indication of 
any metabolic condition, including type 2 diabetes, hyper-
tension, or dyslipidemia, was utilized for this study. Patient 
data included demographic information, vital signs, labora-
tory orders and results, medication list entries, prescription 
orders, diagnoses, and problem lists.
Case study #1:   Assessment of physician prescribing 
for primary care patients with COPD in a national 
EMR research database (Asche et al 2006)
An EMR database of patients receiving care in primary care 
settings was queried to evaluate physician prescribing for 
COPD patients. This study was intended to provide limited 
access to pulmonary function test (PFT) data to assess phy-
sician prescribing for patients with COPD in accordance 
with Global Initiative for Chronic Obstructive Lung Disease 
Workshop report 1 guidelines (GOLD 2005). Patients with 
COPD (ICD-9 codes of 491.xx, 492.xx, 496) and available 
PFTs were identiﬁ  ed and then stratiﬁ  ed by GOLD sever-
ity classiﬁ  cations. Patients with a history of asthma were 
excluded. Physician prescribing of respiratory medications 
was evaluated from 180 days prior to 210 days post the most 
recent PFT (identiﬁ  ed as the study period). Of 25,544 adult 
patients with COPD, less than 1% (246) met the inclusion 
criteria of having both PFT and prescription data without a 
diagnosis of asthma prior to COPD, indicating either a lack of 
testing in primary care, a lack of documentation, or a limited 
transmission of PFT data into an EMR system. The use of 
maintenance bronchodilators among COPD patients in this 
study was low. Approximately 80% of COPD patients were 
prescribed “any bronchodilator” during the study period. 
When short-acting beta-agonists were not included, this pro-
portion decreased to about 66%. Inhaled corticosteroid (ICS) 
use appeared high among mild/moderate COPD patients and 
ranged from 39% in mild patients to 50% in very severe 
patients. Approximately 8% (severe) to 14% (mild, moder-
ate, and very severe) of COPD patients were not prescribed 
any respiratory medications during the study period. Of the 
study population, 76% had moderate/severe COPD.
Case study #2: COPD early diagnosis and treatment 
initiation
The General Electric Medical Quality Improvement 
Consortium (MQIC) database was queried for COPD 
patients. The expressed purpose of this study was to identify 
patterns of care related to initial diagnosis and/or treatment 
of COPD and explore time to initial treatment and diagnosis 
of COPD with the hopes of assisting earlier diagnosis and 
implementation of treatment. A total of 35,752 patients met 
the initial inclusion with COPD ICD-9 codes of 491.xx, 
492.xx, 496.xx and at least 18 years of age at the time of 
diagnosis. Of these 14,691 had the 6 month history required 
for the analysis. Patients were stratiﬁ  ed by disease severity 
level according to the GOLD report guidelines (Joish et al 
2006). The dataset contained 1.75 million patients at the 
time of this query. It was found that the majority of patients 
(73%) were diagnosed with a nonspeciﬁ  c ICD-9 code (496) 
for COPD, but no further classiﬁ  cation was noted. Diagnosis 
of COPD is often made without PFT results and without 
any recorded history of risk factors. Only 4% of subjects 
that met the inclusion criteria had a recorded PFT, indicat-
ing that contrary to the GOLD treatment guidelines it is not 
routinely used to diagnose, classify, or guide treatment of 
COPD. Of those that did have a PFT recorded and available 
at the time of diagnosis, they had COPD Class 2 or higher. 
Analysis of prescribing patterns conﬁ  rmed that COPD is 
not diagnosed or treated until the later stages of the disease. 
Depending on the class of medication prescribed, the mean 
time between the physician order and the time of diagnosis 
ranged from 389–781 days. Similar results were seen for 
time of symptom related to COPD to time of diagnosis of 
COPD. A reason for this delay in diagnosis and treatment 
may be that many patients were initially misdiagnosed for International Journal of COPD 2008:3(2) 325
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Table 1 Results and conclusions from each analysis
Case Title Study purpose Data & patient 
population
Results Conclusions
1 Assessment of physician 
prescribing for primary 
care patients with 
COPD in a National 
EMR Research Database
The assessment of 
physician prescribing 
using a national EMR 
research database for 
patients with COPD vs. 
GOLD guidelines with 
limited availability of 
PFT data to determine 
disease severity.
This study was intended 
to assess prescribing vs. 
guidelines.
GE
•   A national EMR 
research database of 
patients receiving care 
in primary care settings 
was queried.
•   Patients with COPD 
were stratiﬁ  ed by 
GOLD severity 
classiﬁ  cations.
•   Patients with a history 
of asthma were 
excluded.
•   Physician prescribing 
of respiratory 
medications was 
evaluated the most 
recent PFT for the 
study period.
•   Initial data cut = 25,544
•   Only 246 had both PFT 
and prescription data 
without a diagnosis of 
asthma prior to COPD.
•   Of the study population, 
76% had moderate/
severe COPD.
•   Approximately 80% 
of COPD patients 
were prescribed a 
bronchodilator. When 
SAB were not included, 
this proportion 
decreased to about 66%.
•   ICS use ranged from 39% 
in mild patients to 50% in 
very severe patients.
•   Approximately 8%–14% 
(all severity levels) of 
COPD patients were 
not prescribed any 
respiratory medications.
•   1% of COPD 
patients in the database 
had PFT data, indicating 
either a lack of testing, 
documentation, or 
limited transmission of 
PFT data into the EMR 
system.
•   The use of 
maintenance broncho-
dilators among COPD 
patients was low.
•   ICS use appeared high 
among mild/moderate 
COPD patients.
2 COPD early diagnosis 
and treatment initiation
Identify patterns of 
care related to COPD 
exploring time to 
initial treatment and 
diagnosis of COPD 
stratiﬁ  ed by disease 
severity level according 
to the GOLD report 
for COPD to facilitate 




•   The GE centricity data-
base contained 1.75 
million patients at the 
time of this query.
•   14,691 had the 
6 month history 
required.
•   Initial data cut = 35,752 
with the COPD ICD-9 
codes.
•   Only 4% of COPD 
patients had any 
recorded PFT and were 
a Class 2 or higher 
according to GOLD 
guidelines.
•   73% of patients had an 
ICD-9 code for general 
COPD, but were not 
further classiﬁ  ed.
•   The mean time between 
the physician order and 
the time of diagnosis 
ranged from 389–781 
days. Similar results were 
seen when symptoms 
were analyzed.
•   Many patients were 
initially misdiagnosed for 
asthma (32%) or acute 
bronchitis (28%).
•   COPD is not diagnosed 
or treated until later 
classes.
•   PFTs are not routinely 
used to diagnose, 
classify or guide 
treatment of COPD.
•   Diagnosis of COPD is 
often made without 
PFT results and 
without any recorded 
risk factors.
Abbreviations: SAB, short-acting bronchodilators; PFTs, pulmonary function tests; COPD, chronic obstructive pulmonary disease; EMR, electronic medical records; ICS, 
inhaled corticosteroid.
asthma (32%) or acute bronchitis (28%) before then being 
diagnosed for COPD.
Discussion
In this article, two cases or analyses are presented using the 
same database. The data contained has inherent qualities mak-
ing research both challenging and advantageous (Table 2).
Both case studies utilized the MQIC database. The 
advantage of this database was the total amount of speciﬁ  c 
information regarding each patient. It contained demographic 
information, vital signs, laboratory orders and results, clini-
cal outcomes, payment plans, type of payment, prescription 
and OTC medications, and medication lists. However, pos-
sibly due to recording failure, spirometry data was scarce. International Journal of COPD 2008:3(2) 326
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Table 2 Advantages and limitations of the national EMR database
Case Database Advantages Challenges
1 and 2 GE
The General Electric MQIC database
•   Large database which included: 
demographic information, 
vital signs, spirometry data (to 
determine disease severity), labs, 
outcomes, payment plans, type 
of payment, and medications 
including OTC.
•   Less than 1% of COPD patients in 
the database had spirometry data.
•   For the most part, the EMR only 
captures primary care physician 
prescribing. Cannot distinguish 
primary care physicians and 
specialists.
•   Prescription data was analyzed 
and de-identiﬁ  ed and due to this 
62% of the patients had one or 
more medication lines blocked.
•   Oxygen use was captured 
through medical diagnosis rather 
prescription orders.
Abbreviations: MQIC, General Electric Medical Quality Improvement Consortium.
Also, apparently oxygen use was more often captured through 
medical claims rather than prescription claims. This indicated 
that researchers may need to truly look for the data they are 
searching for in unexpected places. Another challenge was 
that one could not distinguish care provided by primary care 
provider (PCP) versus specialist. The ﬁ  nal challenge of this 
database, after de-identiﬁ  cation of patient data for HIPAA 
requirements, is that researchers are left with a large portion 
of text derived data blocked and unattainable due to potential 
identifying language.
Conclusions
Healthcare information collected in the database described 
within this report are generally being collected for alterna-
tive reasons than patient outcome research. Despite various 
methods used to make data consistent, there are inherent 
deﬁ  ciencies that impact the quality of this data for research 
purposes. Researchers must consider the research ques-
tions and desired endpoints when choosing a data source to 
minimize the limitations. Ultimately the contribution of well 
designed studies across various databases, in combination 
with information from randomized clinical trials, can provide 
important information towards health care management and 
policy decisions.
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